Improved survival with the patients with variceal bleed.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3170765)

Published in Int J Hepatol on July 07, 2011

Authors

Praveen Sharma1, Shiv K Sarin

Author Affiliations

1: Department of Hepatology and Transplant Hepatology, Institute of Liver & Biliary Sciences, New Delhi 110 070, India.

Articles cited by this

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44

Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22

Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2010) 5.78

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09

Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2005) 3.68

Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med (1988) 3.53

The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33

Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology (2003) 3.19

Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90

Antibiotic prophylaxis in gastrointestinal endoscopy. Gut (2009) 2.65

Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology (1982) 2.60

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology (2002) 2.49

Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology (2004) 2.49

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43

The natural history of cirrhosis. I. Survival with esophageal varices. N Engl J Med (1963) 2.41

The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology (2005) 2.28

Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med (1968) 2.23

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18

Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med (1993) 2.16

Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15

Improving prognosis following a first variceal haemorrhage over four decades. Gut (2001) 2.14

Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc (2008) 2.08

Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci (1986) 2.07

ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc (2005) 1.99

Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol (2003) 1.95

Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis (2001) 1.91

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87

Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology (2004) 1.78

Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev (2002) 1.73

Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology (1992) 1.71

Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64

Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology (2004) 1.61

Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol (2007) 1.60

Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1998) 1.57

Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology (2004) 1.55

Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology (2006) 1.54

The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy (2006) 1.41

Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol (2000) 1.39

The life history of patients with cirrhosis of the liver and bleeding esophageal varices. Ann Surg (1955) 1.32

Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology (1995) 1.24

Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 1.12

Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology (2003) 1.11

Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology (1986) 1.09

Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology (1996) 1.08

Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev (2003) 1.04

The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol (1998) 1.01

Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology (2001) 1.01

Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality. Dig Liver Dis (2006) 0.96

Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. J Korean Med Sci (2006) 0.94

Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology (1986) 0.93

Assessment of the risk of bleeding from esophageal varices by continuous monitoring of portal pressure. Gastroenterology (1991) 0.92

Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology (2001) 0.92

Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology (2001) 0.90

Prediction of outcome following acute variceal haemorrhage. Br J Surg (1985) 0.87

Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Hepatology (1999) 0.87

Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev (2010) 0.85

Long-term prognosis of patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J Gastroenterol (1989) 0.83

Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial. Eur J Gastroenterol Hepatol (2005) 0.83

Prevention of infectious complications after transjugular intrahepatic portosystemic shunt in cirrhotic patients with a single dose of ceftriaxone. Hepatogastroenterology (1999) 0.81

Articles by these authors

Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology (2008) 3.26

Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 2.11

Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol (2005) 1.45

Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol (2011) 1.44

Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. J Hepatol (2012) 1.42

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol (2003) 1.36

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.33

Endoscopic biliary drainage for severe acute cholangitis in biliary obstruction as a result of malignant and benign diseases. J Gastroenterol Hepatol (2004) 1.32

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol (2008) 1.27

Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol (2006) 1.20

Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol (2010) 1.17

Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet (2002) 1.11

Endoscopic management of postoperative bile leaks. Hepatobiliary Pancreat Dis Int (2006) 1.10

Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol (2013) 1.08

Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol (2007) 1.08

Endoscopic management of acute cholangitis in elderly patients. World J Gastroenterol (2006) 1.02

Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol (2004) 1.01

Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India. J Med Virol (2006) 0.98

Transmission of G145R mutant of HBV to an unrelated contact. J Med Virol (2005) 0.94

Baculovirus as mammalian cell expression vector for gene therapy: an emerging strategy. Mol Ther (2002) 0.94

Minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol (2008) 0.91

Transient elastographic evaluation in adult subjects without overt liver disease: influence of alanine aminotransferase levels. J Gastroenterol Hepatol (2011) 0.91

Management of acute hepatitis B and reactivation of hepatitis B. Liver Int (2013) 0.89

Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int (2012) 0.88

Molecular epidemiology and transmission of hepatitis B virus in close family contacts of HBV-related chronic liver disease patients. J Med Virol (2003) 0.87

Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol (2002) 0.86

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol (2007) 0.86

Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol (2002) 0.85

CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World J Gastroenterol (2006) 0.85

Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int (2014) 0.85

Overexpression of microRNA-30a inhibits hepatitis B virus X protein-induced autophagosome formation in hepatic cells. FEBS J (2015) 0.84

Genetic polymorphisms of CYP2E1 and DNA repair genes HOGG1 and XRCC1: association with hepatitis B related advanced liver disease and cancer. Gene (2013) 0.83

Histological spectrum of chronic hepatitis in precore mutants and wild-type hepatitis B virus infection. Trop Doct (2004) 0.83

Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int (2008) 0.82

Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling. J Gastroenterol Hepatol (2011) 0.82

Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int (2013) 0.82

Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol (2012) 0.82

Eosinophilic abscesses: a new facet of hepatic visceral larva migrans. Abdom Imaging (2013) 0.81

The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol (2006) 0.81

Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. J Gastroenterol Hepatol (2008) 0.81

Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol (2009) 0.81

Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3. J Med Virol (2014) 0.80

Predictors of histological activity and fibrosis in chronic Hepatitis C infection: a study from North India. Indian J Pathol Microbiol (2010) 0.79

Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection. AIDS (2013) 0.79

Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology (2009) 0.79

Liver regeneration during acute-on-chronic liver failure using growth factors: in vivo or ex vivo indulgence of bone marrow? Gastroenterology (2013) 0.79

Efficacy of Shanvac-B recombinant DNA hepatitis B vaccine in health care workers of Northern India. Hepatobiliary Pancreat Dis Int (2010) 0.78

Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients. J Gastroenterol Hepatol (2002) 0.78

Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int (2014) 0.78

Hepatic coagulopathy-intricacies and challenges; a cross-sectional descriptive study of 110 patients from a superspecialty institute in North India with review of literature. Blood Coagul Fibrinolysis (2013) 0.78

Histological profile of liver disease in patients with dual hepatitis B and C virus infection. Indian J Pathol Microbiol (2003) 0.78

Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study. J Gastroenterol Hepatol (2005) 0.77

Contrast-enhanced US-guided radiofrequency ablation of hepatocellular carcinoma. J Vasc Interv Radiol (2013) 0.77

A rabbit model of non-cirrhotic portal hypertension by repeated injections of E.coli through indwelling cannulation of the gastrosplenic vein. Hepatobiliary Pancreat Dis Int (2004) 0.77

Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver disease. Gastroenterology (2009) 0.75

Anticoagulant thepary for portal vein thrombosis in liver: is it worth a buy? Gastroenterology (2013) 0.75

Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes Metab Syndr (2012) 0.75

Identification and full-length molecular characterization of rare hepatitis C virus genotype 5a from India. Arch Virol (2014) 0.75

Endoscopically diagnosed fistula between hepatic artery and first part of duodenum as a cause of massive upper gastrointestinal hemorrhage. Trop Gastroenterol (2012) 0.75

Seroprevalence of Blood Borne Pathogens among Health Care Workers and Their Hepatitis B Vaccination Status in Tertiary Care Hospitals in India. Glob J Health Sci (2016) 0.75

Steatohepatitic variant hepatocellular carcinoma: a case report of new histological variant. Trop Gastroenterol (2014) 0.75

[Similarities and differences in definition and clinical diagnosis of acute-on-chronic liver failure: East vs. West]. Zhonghua Gan Zang Bing Za Zhi (2014) 0.75

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Rev Gastroenterol Hepatol (2008) 0.75

Cirrhotic patients with large esophageal varices and older age have poor hemodynamic response to terlipressin. Eur J Gastroenterol Hepatol (2015) 0.75

Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children. Vaccine (2002) 0.75